Immunohistochemistry of pulmonary biomarkers a perspective from members of the pulmonary pathology society

Erik Thunnissen; Timothy Craig Allen; Julien Adam; Dara L. Aisner; Mary Beth Beasley; Alain C. Borczuk; Philip T. Cagle; Vera Luiza Capelozzi; Wendy Cooper; Lida P. Hariri; Izidor Kern; Sylvie Lantuejoul; Ross Miller; Mari Mino-Kenudson; Teodora Radonic; Kirtee Raparia; Natasha Rekhtman; Sinchita Roy-Chowdhuri; Prudence Russell; Frank Schneider; Lynette M. Sholl; Ming Sound Tsao; Marina Vivero; Yasushi Yatabe

doi:10.5858/arpa.2017-0106-SA

Immunohistochemistry of pulmonary biomarkers a perspective from members of the pulmonary pathology society

Erik Thunnissen, Timothy Craig Allen, Julien Adam, Dara L. Aisner, Mary Beth Beasley, Alain C. Borczuk, Philip T. Cagle, Vera Luiza Capelozzi, Wendy Cooper, Lida P. Hariri, Izidor Kern, Sylvie Lantuejoul, Ross Miller, Mari Mino-Kenudson, Teodora Radonic, Kirtee Raparia, Natasha Rekhtman, Sinchita Roy-Chowdhuri, Prudence Russell, Frank SchneiderLynette M. Sholl, Ming Sound Tsao, Marina Vivero, Yasushi Yatabe

Pathology

Research output: Contribution to journal › Review article › peer-review

65 Scopus citations

Abstract

The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK and programmed death ligand-1 (PD-L1) (ROS1, EGFR in Europe) testing. Handling along proper methodologic lines is needed to ensure patients receive the most accurate and representative test outcomes.

Original language	English (US)
Pages (from-to)	408-419
Number of pages	12
Journal	Archives of Pathology and Laboratory Medicine
Volume	142
Issue number	3
DOIs	https://doi.org/10.5858/arpa.2017-0106-SA
State	Published - Mar 2018

ASJC Scopus subject areas

Pathology and Forensic Medicine
Medical Laboratory Technology

Access to Document

10.5858/arpa.2017-0106-SA

Cite this

Thunnissen, E., Allen, T. C., Adam, J., Aisner, D. L., Beasley, M. B., Borczuk, A. C., Cagle, P. T., Capelozzi, V. L., Cooper, W., Hariri, L. P., Kern, I., Lantuejoul, S., Miller, R., Mino-Kenudson, M., Radonic, T., Raparia, K., Rekhtman, N., Roy-Chowdhuri, S., Russell, P., ... Yatabe, Y. (2018). Immunohistochemistry of pulmonary biomarkers a perspective from members of the pulmonary pathology society. Archives of Pathology and Laboratory Medicine, 142(3), 408-419. https://doi.org/10.5858/arpa.2017-0106-SA

Thunnissen, E, Allen, TC, Adam, J, Aisner, DL, Beasley, MB, Borczuk, AC, Cagle, PT, Capelozzi, VL, Cooper, W, Hariri, LP, Kern, I, Lantuejoul, S, Miller, R, Mino-Kenudson, M, Radonic, T, Raparia, K, Rekhtman, N, Roy-Chowdhuri, S, Russell, P, Schneider, F, Sholl, LM, Tsao, MS, Vivero, M & Yatabe, Y 2018, 'Immunohistochemistry of pulmonary biomarkers a perspective from members of the pulmonary pathology society', Archives of Pathology and Laboratory Medicine, vol. 142, no. 3, pp. 408-419. https://doi.org/10.5858/arpa.2017-0106-SA

@article{4ef0ca38081149de84fcde623905c3c6,

title = "Immunohistochemistry of pulmonary biomarkers a perspective from members of the pulmonary pathology society",

abstract = "The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK and programmed death ligand-1 (PD-L1) (ROS1, EGFR in Europe) testing. Handling along proper methodologic lines is needed to ensure patients receive the most accurate and representative test outcomes.",

author = "Erik Thunnissen and Allen, {Timothy Craig} and Julien Adam and Aisner, {Dara L.} and Beasley, {Mary Beth} and Borczuk, {Alain C.} and Cagle, {Philip T.} and Capelozzi, {Vera Luiza} and Wendy Cooper and Hariri, {Lida P.} and Izidor Kern and Sylvie Lantuejoul and Ross Miller and Mari Mino-Kenudson and Teodora Radonic and Kirtee Raparia and Natasha Rekhtman and Sinchita Roy-Chowdhuri and Prudence Russell and Frank Schneider and Sholl, {Lynette M.} and Tsao, {Ming Sound} and Marina Vivero and Yasushi Yatabe",

year = "2018",

month = mar,

doi = "10.5858/arpa.2017-0106-SA",

language = "English (US)",

volume = "142",

pages = "408--419",

journal = "Archives of Pathology and Laboratory Medicine",

issn = "0003-9985",

publisher = "College of American Pathologists",

number = "3",

}

TY - JOUR

T1 - Immunohistochemistry of pulmonary biomarkers a perspective from members of the pulmonary pathology society

AU - Thunnissen, Erik

AU - Allen, Timothy Craig

AU - Adam, Julien

AU - Aisner, Dara L.

AU - Beasley, Mary Beth

AU - Borczuk, Alain C.

AU - Cagle, Philip T.

AU - Capelozzi, Vera Luiza

AU - Cooper, Wendy

AU - Hariri, Lida P.

AU - Kern, Izidor

AU - Lantuejoul, Sylvie

AU - Miller, Ross

AU - Mino-Kenudson, Mari

AU - Radonic, Teodora

AU - Raparia, Kirtee

AU - Rekhtman, Natasha

AU - Roy-Chowdhuri, Sinchita

AU - Russell, Prudence

AU - Schneider, Frank

AU - Sholl, Lynette M.

AU - Tsao, Ming Sound

AU - Vivero, Marina

AU - Yatabe, Yasushi

PY - 2018/3

Y1 - 2018/3

N2 - The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK and programmed death ligand-1 (PD-L1) (ROS1, EGFR in Europe) testing. Handling along proper methodologic lines is needed to ensure patients receive the most accurate and representative test outcomes.

AB - The use of immunohistochemistry for the determination of pulmonary carcinoma biomarkers is a well-established and powerful technique. Immunohistochemisty is readily available in pathology laboratories, is relatively easy to perform and assess, can provide clinically meaningful results very quickly, and is relatively inexpensive. Pulmonary predictive biomarkers provide results essential for timely and accurate therapeutic decision making; for patients with metastatic non-small cell lung cancer, predictive immunohistochemistry includes ALK and programmed death ligand-1 (PD-L1) (ROS1, EGFR in Europe) testing. Handling along proper methodologic lines is needed to ensure patients receive the most accurate and representative test outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85042635867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042635867&partnerID=8YFLogxK

U2 - 10.5858/arpa.2017-0106-SA

DO - 10.5858/arpa.2017-0106-SA

M3 - Review article

C2 - 28686497

AN - SCOPUS:85042635867

SN - 0003-9985

VL - 142

SP - 408

EP - 419

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

IS - 3

ER -

Immunohistochemistry of pulmonary biomarkers a perspective from members of the pulmonary pathology society

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this